Merck, Inc.
🇺🇸United States
MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)
Phase 2
Completed
- Conditions
- Aspergillosis
- First Posted Date
- 2004-02-06
- Last Posted Date
- 2015-01-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 55
- Registration Number
- NCT00076869
Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)
Phase 2
Completed
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2003-12-16
- Last Posted Date
- 2015-07-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 512
- Registration Number
- NCT00074529
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
Phase 2
Terminated
- Conditions
- Carcinoma, Squamous CellHead and Neck Neoplasms
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00073450
Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)
- First Posted Date
- 2003-05-12
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 46
- Registration Number
- NCT00060632
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
- First Posted Date
- 2003-05-12
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 33
- Registration Number
- NCT00060645
- Locations
- 🇺🇸
Cancer Therapy and Research Center, University of Texas Health Center at San Antonio, San Antonio, Texas, United States
Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
Phase 3
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15000
- Registration Number
- NCT00060476
Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
Phase 2
Completed
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT00056147
Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)
Phase 3
Terminated
- Conditions
- Carcinoma, Non-small-cell LungMetastases, Neoplasm
- First Posted Date
- 2002-12-05
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 702
- Registration Number
- NCT00050336
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
Phase 3
Completed
- Conditions
- Chronic Hepatitis CLiver Fibrosis
- Interventions
- Biological: peginterferon alfa-2b (SCH 54031)
- First Posted Date
- 2002-11-15
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 540
- Registration Number
- NCT00049842
Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)
Phase 3
Completed
- Conditions
- CirrhosisChronic Hepatitis C
- Interventions
- Biological: peginterferon alfa-2b (SCH 54031)
- First Posted Date
- 2002-11-08
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 631
- Registration Number
- NCT00048724
© Copyright 2025. All Rights Reserved by MedPath